Exclusive Summary

• Disruptive Ultra-Long Dosing Interval: With a half-life of 33.4 days, UB664 enables monthly or even once-every-three-month subcutaneous injections, perfectly solving the compliance pain points of current weekly GLP-1 regimens.
• Robust Efficacy Without Dose Titration: A single injection in NHP models resulted in up to 11.8% weight loss at 5 weeks with sustained glucose control, while completely eliminating the cumbersome dose titration process required by conventional GLP-1s.
• Highly Differentiated Modality: As a novel oligonucleotide-based GLP-1 receptor agonist, it offers strong IP protection and mechanistic innovation in a crowded landscape of peptides and small molecules.
• Broad Indication Expansion Potential: Beyond targeting the massive $100B+ T2D and obesity markets, it proactively expands into neurodegenerative diseases (Alzheimer's and Parkinson's), significantly elevating its commercial ceiling.

Asset Materials

Contact Us for Full Materials